Top

Cancer Cell International

Published in:

01-12-2020 | osteosarcoma | Review

Long noncoding RNAs as potential biomarkers in retinoblastoma: a systematic review and meta-analysis

Authors: Jiali Wu, Dashi Qian, Xiaodong Sun

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

Retinoblastoma is the most common malignant rare intraocular tumor of childhood. Long noncoding RNAs (lncRNAs) have been reported participating in its progression, but their significance remains inconclusive. We conducted this systematic review and meta-analysis to explore specific lncRNA biomarker in patients with retinoblastoma.

Materials and methods

Eligible articles were searched from the Pubmed, Web of Science, Embase and the Cochrane library. Hazard ratios (HRs) and odds ratios (ORs) were extracted or calculated to evaluate the relationship between lncRNAs and retinoblastoma. The meta-analysis part was conducted with STATA v.15 software.

Results

A total of 9 articles with 834 retinoblastoma patients are yielded. Heterogeneity among HRs of overall survival (OS) is notably high (I² = 91.3%, p < 0.001). Subgroup analysis suggests that elevated expression of lncRNA BDNF-AS and MT1JP are favorable factors in OS (pooled HR = 1.89, 95% CI 1.72–2.07, I² = 0%). Six articles included optic nerve invasion as a clinicopathological outcome and showed a notable correlation (pooled HR = 2.38, 95% CI 1.26–3.50, I² = 0.0%). We validate our analysis via the public dataset and also sum up the studies of lncRNA BDNF-AS and MT1JP in other cancers.

Conclusion

Differential expression of lncRNAs has been reported in retinoblastoma. Some of them showed potential in retinoblastoma prognosis and progression.

Yahaya JJ, Rugwizangoga B, Mremi A, Munema A. Clinicopathological findings of retinoblastoma: a 10-year experience from a tertiary hospital in Kampala, Uganda. J Ophthalmol. 2019;2019:5829284. https://doi.org/10.1155/2019/5829284(Published 2019 Jun 16).PubMedPubMedCentral

Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021. https://doi.org/10.1038/nrdp.2015.21(Published 2015 Aug 27).PubMedPubMedCentral

Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93(9):1129–31. https://doi.org/10.1136/bjo.2008.150292.PubMed

Gudiseva HV, Berry JL, Polski A, Tummina SJ, O’Brien JM. Next-generation technologies and strategies for the management of retinoblastoma. Genes. 2019;10(12):1032. https://doi.org/10.3390/genes10121032(Published 2019 Dec 11).PubMedCentral

Gao J, Zeng J, Guo B, et al. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine. 2016;95(42):e5204. https://doi.org/10.1097/md.0000000000005204.PubMedPubMedCentral

Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS. Retinoblastoma. Lancet. 2012;379(9824):1436–46. https://doi.org/10.1016/S0140-6736(11)61137-9(ISSN 0140-6736).PubMed

Li J, Li Z, Zheng W, et al. LncRNA-ATB: an indispensable cancer-related long noncoding RNA. Cell Prolif. 2017;50:e12381. https://doi.org/10.1111/cpr.12381.PubMedCentral

Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81. https://doi.org/10.1158/0008-5472.can-16-2634.PubMed

Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50(12):1705–15. https://doi.org/10.1038/s41588-018-0252-3.PubMedPubMedCentral

10.

Wu XZ, Cui HP, Lv HJ, Feng L. Knockdown of lncRNA PVT1 inhibits retinoblastoma progression by sponging miR-488-3p. Biomed Pharmacother. 2019;112:108627. https://doi.org/10.1016/j.biopha.2019.108627(ISSN 0753-3322).PubMed

11.

Hao F, Mou Y, Zhang L, Wang S, Yang Y. LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma. Biosci Rep. 2018;38(3):BSR20180384. https://doi.org/10.1042/bsr20180384.PubMedPubMedCentral

12.

Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q. LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells. J Cell Mol Med. 2018;22(10):5083–96. https://doi.org/10.1111/jcmm.13796.PubMedPubMedCentral

13.

Su S, Gao J, Wang T, Wang J, Li H, Wang Z. Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma. Tumor Biol. 2015;36(9):7205–11. https://doi.org/10.1007/s13277-015-3413-3.

14.

Li L, Chen W, Wang Y, Tang L, Han M. Long non-coding RNA H19 regulates viability and metastasis, and is upregulated in retinoblastoma. Oncol Lett. 2018;15(6):8424–32. https://doi.org/10.3892/ol.2018.8385.PubMedPubMedCentral

15.

Wang J-X, Yang Y, Li K. Long noncoding RNA DANCR aggravates retinoblastoma through miR-34c and miR-613 by targeting MMP-9. J Cell Physiol. 2018;233:6986–95. https://doi.org/10.1002/jcp.26621.PubMed

16.

Yan Guigang, Su Yi, Ma Zhao, Yu Lianzhi, Chen Ning. Long noncoding RNA LINC00202 promotes tumor progression by sponging miR-3619-5p in retinoblastoma. Cell Struct Funct. 2019;44:51–60. https://doi.org/10.1247/csf.18033.PubMed

17.

Bi LL, Han F, Zhang XM, Li YY. LncRNA MT1JP acts as a tumor inhibitor via reciprocally regulating Wnt/beta-catenin pathway in retinoblastoma. Eur Rev Med Pharmacol Sci. 2018;22(13):4204–14. https://doi.org/10.26355/eurrev_201807_15414.PubMed

18.

Shang W, Yang Y, Zhang J, Wu Q. Long noncoding RNA BDNF-AS is a potential biomarker and regulates cancer development in human retinoblastoma. Biochem Biophys Res Commun. 2018;497(4):1142–8. https://doi.org/10.1016/j.bbrc.2017.01.134(ISSN 0006-291X).PubMed

19.

Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene. 2018;37:1551–60. https://doi.org/10.1038/s41388-017-0050-x.PubMed

20.

Kim JW. Retinoblastoma. Int Ophthalmol Clin. 2015;55(1):77–96. https://doi.org/10.1097/iio.0000000000000048.PubMed

21.

Berry JL, Zolfaghari E, Chen A, Murphree AL, Jubran R, Kim JW. Optic nerve obscuration in retinoblastoma: a risk factor for optic nerve invasion? Ocul Oncol Pathol. 2017;3(4):283–91. https://doi.org/10.1159/000464468.PubMedPubMedCentral

22.

Rajasekaran S, Nagarajha Selvan LD, Dotts K, et al. Non-coding and coding transcriptional profiles are significantly altered in pediatric retinoblastoma tumors. Front Oncol. 2019;9:221. https://doi.org/10.3389/fonc.2019.00221(Published 2019 Apr 16).PubMedPubMedCentral

23.

Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr. 2017;84:937–44. https://doi.org/10.1007/s12098-017-2395-0.PubMed

24.

Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor: a review. J Neurosci Res. 2019;97(1):29–44. https://doi.org/10.1002/jnr.24213.PubMed

25.

Plousiou M, Vannini I. Non-coding RNAs in retinoblastoma. Front Genet. 2019;10:1155. https://doi.org/10.3389/fgene.2019.01155(Published 2019 Nov 14).PubMedPubMedCentral

26.

Zhao H, Diao C, Wang X, et al. LncRNA BDNF-AS inhibits proliferation, migration, invasion and EMT in oesophageal cancer cells by targeting miR-214. J Cell Mol Med. 2018;22(8):3729–39. https://doi.org/10.1111/jcmm.13558(published online ahead of print, 2018 Jun 12).PubMedCentral

27.

Zhang H, Liu C, Yan T, Wang J, Liang W. Long noncoding RNA BDNF-AS is downregulated in cervical cancer and has anti-cancer functions by negatively associating with BDNF. Arch Biochem Biophys. 2018;646:113.PubMed

28.

Zhi H, Lian J. LncRNA BDNF-AS suppresses colorectal cancer cell proliferation and migration by epigenetically repressing GSK-3β expression. Cell Biochem Funct. 2019. https://doi.org/10.1002/cbf.3403.PubMed

29.

Li W, Dou Z, We S, Zhu Z, Pan D, Jia Z, Liu H, Wang X, Yu G. Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer. Biomed Pharmacother. 2018;102:1105–10.PubMed

30.

Huang Q, Yang J, He X, Shi S, Xing S. LncRNA BDNF-AS is associated with the malignant status and regulates cell proliferation and apoptosis in osteosarcoma. Biosci Rep. 2018;38(6):BSR20181498. https://doi.org/10.1042/bsr20181498(Published 2018 Nov 15).PubMedPubMedCentral

31.

Esfandi F, Bouraghi H, Glassy MC, et al. Brain-derived neurotrophic factor downregulation in gastric cancer. J Cell Biochem. 2019;120:17831–7. https://doi.org/10.1002/jcb.29050.PubMed

32.

Xu Y, Zhang G, Zou C, Zhang H, Gong Z, Wang W, Zhang W. LncRNA MT1JP suppresses gastric cancer cell proliferation and migration through MT1JP/MiR-214-3p/RUNX3 Axis. Cell Physiol Biochem. 2018;46(6):2445–59. https://doi.org/10.1159/000489651.PubMed

33.

Zhang G, Li S, Lu J, et al. LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018;17(1):87. https://doi.org/10.1186/s12943-018-0829-6(Published 2018 May 2).PubMedPubMedCentral

34.

Zhu D, Zhang X, Lin Y, Liang S, Song Z, Dong C. MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p. Am J Transl Res. 2019;11(1):245–56 (Published 2019 Jan 15).PubMedPubMedCentral

35.

Yu H, Wang S, Zhu H, Rao D. LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. J Cell Physiol. 2019. https://doi.org/10.1002/jcp.28274.PubMedPubMedCentral

36.

Ma J, Yan H, Zhang J, Tan Y, Gu W. Long-chain non-coding RNA (lncRNA) MT1JP suppresses biological activities of lung cancer by regulating miRNA-423-3p/Bim axis. Med Sci Monit. 2019;25:5114–26. https://doi.org/10.12659/msm.914387(Published 2019 Jul 10).PubMedPubMedCentral

Title: Long noncoding RNAs as potential biomarkers in retinoblastoma: a systematic review and meta-analysis
Authors: Jiali Wu
Dashi Qian
Xiaodong Sun
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: osteosarcoma
Retinoblastoma
Osteosarcoma
Retinoblastoma
Biomarkers
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01281-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma

A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts

Long noncoding RNA NEAT1 regulates radio-sensitivity via microRNA-27b-3p in gastric cancer

Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma

Expression and function of transmembrane 4 superfamily proteins in digestive system cancers

Pathological role of ion channels and transporters in the development and progression of triple-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer